Transmission and the Respiratory Tract in Cryptosporidiosis
December 2, 2009 updated by: Tufts University
Prevalence and Clinical Presentation of Respiratory Cryptosporidiosis Among Children With Diarrhea in Mulago Hospital, Uganda
Cryptosporidium is an intestinal parasite that causes diarrhea in children and adults.
In addition to infection of the stomach, this parasite can infect the respiratory system causing a cough and/or problems breathing.
This study will enroll 480 children between the ages of 9 and 36 months who come to Mulago Hospital for treatment of diarrhea.
Researchers believe a large number of children with diarrhea and cough will have the parasite present in their sputum (mucus coughed up).
Researchers also believe that children who have respiratory tract cryptosporidiosis may have a cough, increased number of breaths per minute, and/or a lower oxygen level.
Blood, stool, saliva, and sputum samples will be collected from all children in the study and tested for Cryptosporidium.
Children too young to provide a sputum sample will have a tube placed to collect a mucus sample from the lungs.
Study participation may be as short as 4 hours or as long as 2 days depending on each child's health.
Study Overview
Status
Completed
Conditions
Detailed Description
Cryptosporidiosis is recognized as a major cause of diarrhea worldwide.
In addition to infection of the gastrointestinal tract and associated fecal-oral transmission, there is evidence that Cryptosporidium can infect the respiratory tract.
Of particular interest are numerous reports indicating that respiratory symptoms occur with considerable frequency in subjects with intestinal cryptosporidiosis although the etiology of the respiratory symptoms was never investigated.
The association between respiratory symptoms and intestinal cryptosporidiosis is particularly strong in children with questionable nutritional status.
This study will evaluate the prevalence and clinical presentation of respiratory cryptosporidiosis among children with diarrhea in Mulago Hospital, Kampala, Uganda.
The study will screen approximately 1536 children aged 9-36 months who present to the Acute Care Unit of Mulago Hospital in Kampala, Uganda, with acute or persistent diarrhea.
Based on the results of fecal testing, 480 children will be actively selected to undergo further sample collection in 2 groups.
Group 1 will be comprised of children with Cryptosporidium-positive stools, approximately 50% of whom are expected to have cough (n=384).
Group 2 will be comprised of children with Cryptosporidium-negative stools and cough (n=96).
The primary objectives of the study are: to establish the prevalence of cough in children with diarrhea due to Cryptosporidium infection; to establish the prevalence of respiratory tract cryptosporidiosis in children with diarrhea due to Cryptosporidium infection; to establish the prevalence of respiratory tract cryptosporidiosis in children with diarrhea due to other causes; and to determine whether respiratory Cryptosporidium infection in children is associated with increased respiratory rates and decreased oxygen saturation levels.
To address these objectives, the study will focus on whether Cryptosporidium oocysts can be recovered from induced sputum of subjects who have acute or persistent diarrhea and are concurrently experiencing a cough or unexplained tachypnea or hypoxemia.
The primary clinical measures include: duration of diarrhea (days); presence and duration of cough (days); respiratory rate at presentation and if dehydrated, after rehydration; oxygen saturation (as measured by pulse oximetry) at presentation; and oxygen therapy requirement and oxygen saturation after 30 minutes of oxygen therapy if initial saturation is <92%.
Primary parasitological measures include: presence or absence of Cryptosporidium in stool (as detected by modified acid fast staining and PCR); presence or absence of Cryptosporidium in sputum (as detected by PCR); and presence or absence of Cryptosporidium in saliva (as detected by PCR).
Secondary clinical measures include: HIV status (determined by voluntary HIV testing via enzyme-linked immunosorbent assay + reverse transcriptase PCR in children aged less than 18 months); CD4+ counts/percentages (as measured by flow cytometry in children tested for HIV); concurrent respiratory infection (as determined by processing of sputum for routine bacterial pathogens, tuberculosis and pneumocystis jirovecii pneumonia; anemia (determined by hemoglobin measurement from complete blood count); and nutritional status (as determined from the weight-for-age score, height-for-age score, weight-for-height score, head circumference, and mid upper arm circumference).
Secondary parasitological measurements include: species of Cryptosporidium in stool, in sputum, and in saliva (as determined by restriction fragment length polymorphism).
Subject participation duration in the study is dependent on the health status of the child at admission and the extent of clinical care required.
In uncomplicated cases, subject duration may be as short as 4 hours.
In subjects requiring extensive clinical care subject duration may extend to 2 days.
Study Type
Observational
Enrollment
480
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kampala, Uganda
- Makerere University Medical School
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
9 months to 3 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Children attending the Acute Care Unit at Mulago Hospital, Kampala, Uganda
Description
Inclusion Criteria:
- Male and female children aged 9-36 months at the time of enrollment
- Presence of acute or persistent diarrhea (diarrhea defined as 3 or more loose stool in the previous 24 hours AND not considered normal for that child if the child is exclusively breast fed OR any number of bloody stools in the previous 24 hours; less than or equal to 14 days duration for acute diarrhea; >14 days duration for persistent diarrhea)
- Child's parent/guardian speaks English or Luganda
- Parent/guardian provides full and free informed consent for child to participate in study
Exclusion Criteria:
- Unknown age
- Known cardiac, CNS, metabolic or endocrine disorders
- Moribund children
- Children with recent history of choking or sudden onset of symptoms with suspected foreign body inhalation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Time Perspectives: Prospective
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeffrery K Griffiths, MD, Tufts Universtiy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
January 1, 2009
Study Completion (Actual)
January 1, 2009
Study Registration Dates
First Submitted
July 26, 2007
First Submitted That Met QC Criteria
July 26, 2007
First Posted (Estimate)
July 27, 2007
Study Record Updates
Last Update Posted (Estimate)
December 3, 2009
Last Update Submitted That Met QC Criteria
December 2, 2009
Last Verified
September 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-0033
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.